The adaptation of cancer cells to therapies limits the effectiveness of treatments. However, understanding the mechanisms they use to do it could help reverse them or be used to design more powerful drugs. Scientists at New York University (NYU) have studied the transitions causing resistance and have observed how it develops through a gradual process they have called the “resistance continuum.” Read More

Age-related inflammation, also known as inflammaging, refers to low-grade chronic damage caused by increased inflammation linked to immunosenescence with impact at molecular, cellular and tissue levels. Aging amplifies the inflammatory response and increases neutrophil, monocyte and leukocyte trafficking in models of inflammation. Read More

Researchers from Shandong University and affiliated organizations reported the discovery and preclinical characterization of novel 68Ga-labeled PSMA-targeting tracers for the diagnosis of prostate cancer. Read More

Scisparc Ltd.’s Mitocarex Bio Ltd. venture has validated the potential significant involvement of its target SLC25 carrier protein, using non-small-cell lung cancer (NSCLC) cells with diverse genetic backgrounds. Mitocarex used genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors, to demonstrate the discovery. Read More

Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation. Read More

Researchers from Shanxi Medical University presented data from a study that aimed to assess the effects of delayed treatment with G protein-coupled receptor 65 (GPR65) agonist BTB-09089 on neurorestoration following ischemic stroke in mice. Read More

From no hope to viable treatments, BioWorld  is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld  team is ‘always on the lookout for what's next.’ Read More

Researchers from CONICET and affiliated organizations presented the discovery of novel llama-derived single-chain antibody fragments (VHHs) specific for type A influenza virus. Read More

Exelixis Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer. Read More

Asieris Pharmaceuticals Co. Ltd. has identified serine/threonine-protein kinase ATR inhibitors reported to be useful for the treatment of cancer. Read More

Researchers from Chongqing Medical University and affiliated organizations reported findings from studies they performed to assess the role of zinc-finger protein 334 (ZNF334) in cervical cancer. Read More

Insilico Medicine Inc. has divulged compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer. Read More

Gasherbrum Bio Inc. has described GLP-1 receptor agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others. Read More

Mira Pharmaceuticals Inc. has released new preclinical study results for its oral ketamine analogue, Ketamir-2, which is under investigation for potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression and post-traumatic stress disorder. Read More